The tumor suppressor protein p53 is one of the most important targets in various cancers including non-small cell lung cancer (NSCLC). The small molecule Nutlin-3 reactivates p53 in cancer cells by interacting with the complex between p53 and its repressor Mdm-2, which leads to increased apoptosis of cancer cells. Nevertheless, clinical and experimental studies of Nutlin-3 have shown that in some cases cancer cells are not sensitive to this compound. In this paper we studied possible mechanisms of such a resistance of cancer cells to Nutlin-3 through increased activity of specific pro-survival pathways that appeared to be more active in the resistant cells, as compared to the cells sensitive to the treatment by this compound. Using genome-wide gene expression profiling we compared several NSCLC cell lines. Nutlin-3 resistant cell lines showed a significantly different gene expression in comparison with sensitive cell lines before and after treatment by Nutlin-3.
maintaining this resistant state. Among them the most promising was mTOR acting in the context of the activated PI3K pathway. With the help of chemical inhibitors, we were able to validate these findings experimentally. The Nutlin-3 resistant cell lines showed the highest sensitivity to the inhibitor of mTOR with PI3K, which lead to the rapid death of these cells.
Introduction
Target therapy is one of the most promising approaches for the treatment of oncological diseases. It performs a targeted pharmacological interaction with specific proteins in the cancer or associated cells (so-called pharmacological molecular target). One of the most important targets in cancer cells is the well known tumor suppressor protein p53.
Among known small molecules interacting with p53 the compound called Nutlin-3 gives rise to promising drug candidates for treatment of various cancers [1] [2] . Through interaction with the complex between p53 and its repressor Mdm-2 the compound Nutlin-3 increases the activity of p53 which in turn leads to an increased apoptosis of cancer cells. Nevertheless, clinical and experimental studies of Nutlin-3 showed that in some cases cancer cells are not sensitive to this compound. One of the possible mechanisms of such resistance of cancer cells to Nutlin-3 is an increased activity of several pro-survival pathways that are regulated by specific signaling mechanisms in the cells. These pathways appeared to be more active in the resistant cells compared to the cells sensitive to the treatment by this compound. As a result, these tumor cells can avoid apoptosis due to a compensatory effect of these pathways despite the treatment with cytotoxic compounds. Such a highly active pro-survival pathway can either pre-exist in some types of tumor cells or become active upon treatment with cytotoxic compounds.
The group of drugs that reactivate the transcription factor p53 includes such interesting compounds as: nutlins (Nutlin-3); BDAs (benzodiazepinediones); A series of Mdm2 inhibitors (MI-63, MI-219 and MI-43); Tenovin (Tenovin-6); RITA, PRIMA-1, CP-31398, MIRA-1 and others. These compounds are small molecules with a common antitumor mechanism of action. Namely, the interaction of compounds with the p53 protein leads to the restoration of its functional activity and a subsequent induction of apoptosis in the tumor cell.
In this work, we study the effects of reactivation of p53 in the non-small cell lung cancer (NSCLC) by one of the most promising compounds -Nutlin-3.
The effect of Nutlin-3 leads to the restoration of p53 activity in the cell by inhibiting the interaction of p53 with the protein Mdm2. The Mdm2 protein is an E3 ubiquitin ligase which plays a key role in the regulation of p53 [1] . In the cell, Mdm2 binds to the N-terminal domain of the p53 protein leading to the inactivation and the subsequent proteolytic ubiquitin-dependent degradation of p53. Very often, in tumor cells there is a substantial increase in the expression of Mdm2 [3] . As a result, in such tumor cells a rapid degradation of p53 occurs, which allows them to escape p53-dependent apoptosis. The destruction of the complex Mdm2-p53 promotes the stabilization of p53 and the restoration of its activity, which in turn leads to an inhibition of proliferation and / or death of tumor cells. To date, three classes of small organic molecules have been identified that, due to their structural features, are capable of inhibiting the interaction of Mdm2 and p53. These include heterocyclic compounds: Nutlins (nutlins) [4] , BDAs (benzodiazepindiones) [5] and a series of Mdm2 inhibitors (MI) of spiro-oxindole derivatives including MI-63, MI-219 and MI-43 [6, 7] . All three series of compounds mimic the amino acid residues F19, W23 and L26 of the p53 protein and bind with high affinity to Mdm2 in the p53-specific pocket region and thus displace p53 from the Mdm2-p53 complex.
Of all the compounds inhibiting the interaction of the proteins Mdm2 and p53, nutlins are the best studied. Pre-clinical trial data of the treatment of acute myeloid leukemia with Nutlin-3a for [8, 9] has confirmed the ability of Nutlin-3a to induce apoptosis of tumor cells (but not the normal hematopoietic blood cells). Recently the small molecule drug RG7112 (Roche, Penzberg, Germany) (a derivative compound of Nutlin-3a, which was used as an early lead) was studied in a couple of Phase I clinical trials for advanced solid and hematological cancers, and liposarcoma [1] (clinical trial: NCT00559533), in acute myelogenous leukemia (clinical trial: NCT01635296) and soft tissue sarcoma (clinical trial NCT01605526 done by Roche) delivering reasonably promising results [2] . Still during such studies researchers often observed a decrease of efficiency in cancer inhibition due to the resistance of cancer cells to the treatment by In order to analyze the effect of Nutlin-3 on non-small cell lung cancer and understand the mechanisms of resistance we performed an extensive study of the biological activity of the compounds Nutlin-3 on a number of NSCLC cell lines carrying wild-type TP53 gene. A total of 8 cell lines were analyzed: A549, NCI-H292, A427, COR-L23, DV-90, NCI-H1395, NCI-H1944, NCI-H2228. The cytotoxic activity of Nutlin-3 on NSCLC cells was determined based on the IC50 (inhibitory concentration) parameter (concentration of compound leading to 50% of cell death in a culture). The IC50 parameter was determined using a resazurin viability test. We found that NSCLC cell lines differ significantly from each other in the sensitivity to Nutlin-3.
We chose one of the most Nutlin-3 sensitive cell lines -H1944, and two moderately resistant cell lines -A427 and NCI-H292 for further studies. We performed microarray experiments in these cell lines before and after treatment by Nutlin-3 in order to reveal different gene expression profiles in resistant cell lines. Comparative analysis of microarray data of these three cell lines was performed using a computational pipeline "From genome to target" (http://my-genome-enhancer.com) implemented using BioUML driven systems biology platform (www.biouml.org, www.genexplain.com). We revealed a number of differentially expressed genes (DEGs) between sensitive and resistant cell lines. Promoter and pathway analysis of these DEGs using the "upstream analysis" approach [10] helped us to identify potential master regulators in these cancer cell lines responsible for the elevated resistance to Nutlin-3. Among them, the most promising was mTOR as one of the most important regulators of pro-survival mechanisms in the cell. We applied specific chemical inhibitors in order to test their effect on these cell lines. We found that Nutlin-3 resistant cell lines exhibit the highest sensitivity to the dual chemical inhibitor of mTOR-PI3K whereas the Nutlin-3 sensitive cell line appeared to be relatively insensitive to this inhibitor. These results confirmed our prediction that the master regulators in the mTOR-PI3K signaling pathway are responsible for the elevated resistance of particular NSCLC cell lines to treatment by the p53-reactivating compound Nutlin-3. As we predicted, the Nutlin-3 resistant cell lines appeared to be highly sensitive to the inhibitors of mTOR-PI3K pathway. These findings open a promising possibility for a combinatory therapy combining Nutlin-3 with mTOR-PI3K inhibitors. Such drug combinations will have a potential to tackle the observed heterogeneity between different cancer cell linages towards p53-reactivators such as Nutlin-3.
Data, Materials and Methods
Cell lines. In our study we used the following eight cell lines of non-small cell lung cancer (A549, NCI-H292, A427, COR-L23, DV-90, NCI-H1395, NCI-H1944, and NCI-H2228). The characteristics of these eight cell lines are given in Table 1 . 
Test for vitality with resazurin. Resazurin is an oxidation-reduction dye and is used to
analyze the toxicity of compounds in cell culture [11] . The analysis is based on the ability of metabolically active cells to restore resazurin (a blue product) to resorufin (a pink color product, a fluorophore with absorption and emission maxima at 571 and 586 nm, respectively). The conversion of resazurin to resorufin is carried out intracellularly and is provided by mitochondrial, microsomal and cytosolic oxidoreductases. Thus, the amount of resorufin in the culture medium is related to the total number and (or) survival of the cells in the culture. To obtain optimal conditions for PCR, the structures and combinations of primers, the composition of the amplification buffer, and the parameters of the amplification cycle were varied.
Microarray analysis
Microarray analysis was performed using the following microarray platform: Human HT-12 v3 Expression BeadChips (Illumina). Three cell lines: А427, H292 and H1944 were treated by Nutlin-3 in a cytotoxic concentration (30 µM) and at a concentration that maximally discriminates the sensitive and moderately resistant cell lines (5 µM). The cells were incubated with the compound for 24 hours. The experiment was done in two biological replicates for each condition. In order to detect differentially expressed genes the raw microarray data were normalized and further analyzed using the Limma tools from the R/Bioconductor package integrated into the BioUML driven pipeline "From genome to target". Limma calculated the LogFC (the logarithm on the basis of 2 of the fold change between different conditions) and the p-value and adjusted p-value (corrected to the multiple testing). All these parameters were used to detect differentially expressed genes.
Analysis of Enriched Transcription Factor Binding Sites
Transcription factor binding sites in promoters of differentially expressed genes were analyzed using known DNA-binding motifs described in the TRANSFAC ® library [13] , release 2017.2 (geneXplain, Wolfenbüttel, Germany) (http://genexplain.com/transfac). The motifs are specified using position weight matrices (PWMs) that assign weights to each nucleotide in each position of the DNA binding motif for a transcription factor or a group of them.
The BioUML environment provides tools to identify transcription factor binding sites (TFBS) that are enriched in the promoter regions under study as compared to a background sequence set such as promoters of genes that were not differentially regulated under the condition of the experiment. We denote study and background sets briefly as Yes and No sets. The algorithm for TFBS enrichment analysis, called F-Match, has been initially described in [14] . Briefly, as it has been described in detail previously [10] , the procedure finds a critical value (a threshold) for the score of each PWM in the library that maximizes the Yes/No ratio R YN as defined in Equation (1) under the constraint of statistical significance.
(
In Equation (1) 
Finding Master Regulators in Networks
We searched for master regulator molecules in signal transduction pathways upstream of the identified transcription factors using the BioUML platform tools. The master-regulator search uses the TRANSPATH ® database (http://genexplain.com/transpath) [15] . A comprehensive signal transduction network of human cells is built by the network analysis module of the BioUML platform using reactions annotated in TRANSPATH ® . The main algorithm of the master regulator search has been described earlier [10] . The goal of the algorithm is to find nodes in the global signal transduction network that may potentially regulate the activity of the set of transcription factors found at the previous step of analysis.
Such nodes are considered most potent drug targets, since any influence on such a node may switch the transcriptional programs of hundreds of genes that are regulated by the respective
TFs. In our analysis, we have run the algorithm with a maximum radius of 12 steps upstream of the TFs.
Computational pipeline «From genome to target»
Comparative analysis of microarray data of these three cell lines was performed using a computational pipeline "From genome to target" (http://my-genome-enhancer.com)
implemented on a BioUML-driven systems biology platform (www.biouml.org, www.genexplain.com). The pipeline can take various multi-omics data (such as Genomics, 
a flexible graphical tool for describing meta-data of the experiment that helps researchers to define data for the automatic analysis. The pipeline consists of four modules: Statistics, Genome Enhancer, Drugs, Biomarkers, and Targets. Depending on the input data, meta-data and the chosen parameters, the system generates a tailor-made data analysis workflow going through all these four modules. In the first step, the data is statistically analyzed and the lists of differentially expressed genes (DEGs) (in case of Transcriptomics data), proteins (Proteomics) and metabolites (Metabolomics) are prepared for the next steps of analysis. In the cases of Epigenetic data (ChIP-seq, DNA methylation) a list of statistically significant peaks and CpG methylation sites is prepared for the next step. The Genomics data are also analyzed in this step and lists of revealed mutations are computed in the form of VCF files.
At the Genome Enhancer module, the analysis of gene regulatory regions of differentially expressed genes is performed using the Match™ [10] and CMA [16] tools (which in turn use the TRANSFAC ® [13] , HOCOMOCO [17] and GTRD [18] databases of position weight matrices) in order to detect transcription factor binding sites (TFBSs) in the promoters and enhancers of DEGs. ChIP-seq peaks and CpG methylation sites are used in this module to help to define the enhancer and silencer regions of the differentially expressed genes. In addition, those mutations that were found inside enhancers and silencers are used to reveal transcription factor binding sites significantly affected by these mutations. As a result, a list of transcription factors regulating genes through the identified TFBSs is forwarded to the network analysis in the signal transduction network (using the TRANSPATH ® , REACTOME, and HumanCyc databases). If genomic data is available, then the observed mutations in the coding regions of proteins, which are involved in signal transduction and which damage the function of these proteins, are taken into account. The network is then modified by exclusion of corresponding nodes and reactions from it. The network analysis algorithm reveals master regulators as described above. In pipeline modules "Drugs" and "Biomarkers and Targets" the revealed master-regulators are interrogated and prioritized in order to select the most promising therapeutic targets. Various properties of these masterregulator proteins, such as potential "drugability" (possibility to find known drugs or novel chemical compounds potentially interacting with these proteins) as well as additional annotation from the HumanPSD® (www.genexplain.com/humanpsd) database about known disease relevance of these proteins, are taken into account for such a prioritization. Finally, the pipeline "From genome to target" reports a short list of most promising targets.
Results

Sensitivity of different NSCLC cell lines to Nutlin-3
To test the sensitivity to Nutlin-3 we treated the selected NSCLC cell lines during 24 Cell line H1944 shows a higher sensitivity to the compound as compared to the cell lines H292 and A427. Table 2 one can see the results of detection of Up-and Down-regulated genes (adj.p-value<0.05) in all three conditions. One can see that the untreated cells are characterized by rather high numbers of Table 3 and in Figure 2 . We also see a rapid change of the activated pathways with an increased dosage of treatment by Nutlin-3. 
Enriched Transcription Factor Binding Sites in promoters of Nutlin-3 moderately resistant cell lines
Transcription factor binding sites in promoters of differentially expressed genes were analyzed using known DNA-binding motifs described by PWMs in the TRANSFAC The CMA algorithm applies a genetic algorithm approach to find combinations of PWMs for the co-localized sites in promoters of DEGs. Such combinations of PWMs define groups of transcription factors that bind to the promoters of these genes in a synergistic manner (forming enhanceosomes [20] ) and regulate the expression of their target genes in very specific conditions. In this work, we applied these algorithms to analyze promoters of Up-regulated genes in Nutlin-3 moderately resistant NSCLC cell lines (А427 and H292) in comparison to the Nutlin-3 sensitive cell line H1944. We focused our attention on the up-regulated genes in order to reveal the potential resistance-specific positive feedback loops (as it is described in our previous paper [10] ) that are maintained mainly through gene up-regulation. For the promoter analysis, we restricted the list of up-regulated genes by two criteria: The FC>1.5
(which corresponds to LogFC>0.58) and CI0.95>2.0 (confidence interval 0.95). The second criterion provides higher evidence that these genes are indeed up-regulated and it is applied here due to the very low number of replicas used (only 2 replicas were used in each condition, which is quite the lowest limit for Limma). As a result, we came up with a list of 179 up-regulated genes. As a control for the promoter analysis we selected 1000 genes that did not significantly change their expression between compared conditions (-0.1<LogFC
<0.1).
In order to characterize this more restricted set of upregulated genes a bit further we mapped them to the disease ontology from the HumanPSD ® databases and found a very high enrichment of genes related to different types of cancer (the most statistically significant match is the set of 71 genes to the category "Causative biomarkers of Neoplasms" (pvalue<10 -10 ). 65 of these genes belong to the biomarkers of Lung neoplasms (p-value < 10 -4 ).
We constructed the heatmap for these genes summarizing their expression profiles throughout all obtained microarray data (Fig. 4) . Table 4 below. We also have applied the СМА (Composite Module Analyst) algorithm, which allows to predict the formation of complexes of transcription factors binding sites that could jointly regulate groups of genes, such as up-regulated in our study. As a result, we identified the potential complexes of TFs that may synergistically bind to promoters of these genes and maintain their elevated expression, which in turn leads to the observed relatively high resistance of these cell lines to Nutlun-3.
Results of the CMA analysis are shown on the Figure 5 below. We identified a combination of PWMs that discriminates the promoters of Yes and
No sets rather well. This combination contains PWMs for such important cancer-related transcription factors as p53, beta-catenin, Smad, Tcf12, Klf3, C/EBP and others. The full list of 25 transcription factor genes encoding TFs of selected combinations of PWMs is given in Table 5 . Many of them are associated with various Neoplasms including Lung Neoplasms. The last six columns show with which pathways or GO terms and diseases the selected genes are associated.
Finding Master Regulators in Networks upstream of TFs.
We searched for master regulator molecules in signal transduction pathways upstream of the identified transcription factors. The master-regulator search uses the TRANSPATH ® database (http://genexplain.com/transpath) [15] and is implemented in the workflow "From genome to target" as a last step. The main algorithm of the master regulator search has been described earlier [10] . The goal of the algorithm is to find nodes in the global signal transduction network that may potentially regulate the activity of the set of transcription factors found at the previous step of analysis. Such nodes are considered the most potent drug targets, since any influence on such a node may switch the transcriptional programs of hundreds of genes that are regulated by the respective TFs. In our analysis, we have run the algorithm with a maximum radius of 12 steps upstream of the TFs. In order to identify the potential positive feedback loops in the system we applied additional filtering to the obtained master-regulators. We required that the Composite Score of the genes encoding masterregulators in the system were above the critical value (6.28) computed by the CMA algorithm. This requirement enables us to find those master-regulators that regulate elevated expression of their own genes (through multiple TFBSs found in the promoters of these genes), thus leading to the feedback mechanism of maintaining its own elevated expression.
In Table 6 below we give the final list of obtained master-regulators potentially involved in maintaining elevated resistance to Nutlin-3. Figure 6 shows the diagram of the network constructed by the algorithm of master-regulator search. The network connects the identified top master-regulators (red) with the transcription factors found in the promoter analysis (blue). 
Comparison of the master-molecule network with canonical pathways.
In order to understand which components of canonical pathways are involved in maintaining the resistance of studied cells to Nutlin-3 we mapped the whole identified network connecting potential master-regulators with transcription factors onto the comprehensive collection of pathways in the TRANSPATH ® database. As one can see from the Table 7 the pathways that involve the master regulator mTOR are the well-known pro-survival pathways of PDK1, ACT-1 and PI3K. We found the PI3K sub-pathway especially interesting, which involves mTOR for inhibiting p53 -the main target of Nutlin-3 (see Fig. 7 ). 
Experimental validation of mTOR as master-regulator by chemical inhibitors.
After choosing the master-regulator mTOR as the target molecule we applied specific chemical inhibitors in order to test their effect on the survival of these cell lines. We choose the following chemical inhibitors (Table 8) . To validate the effect of the inhibition of mTOR in the context of PI3K pathways we chose the dual inhibitor C3 that is known to effectively inhibit both PI3K and mTOR action.
To test the mTOR-specificity of the effect we used the general inhibitor of PI3K (C1). And as a negative test we used the inhibitor of Bcl-XL (C2) that is known to be involved in cancer but was not predicted here as a master-regulator.
We used the following treatment conditions for these three compounds.
 C1 in concentrations: 50μM, 25μM, 12,5μM, 6,25μM, 3,1μM and 0μM
 C2 in concentrations: 80μM, 40μM, 20μM, 10μM, 5μM and 0μM (Control);  C3 in concentrations: 50μM, 25μM, 12,5μM, 6,25μM, 3,1μM and 0μM
The concentration of the compounds was chosen according to their maximal solubility in the medium. DMSO was used to prepare the needed concentration of the compounds and the concentration of DMSO was the same in all tested solutions (including Control) and it was below 0.5%. Each measurement was done in three replicas. After 48
hours from adding of the compound we measured the percentage of the survived cells using the test with rezuverin.
We found that compounds C1 and C2 do not demonstrate any cytotoxic activity on all tested cell lines (data not shown). Under any compound concentrations the number of the survived cells were the same as in the Control and did not differ significantly from 100%. We found that Nutlin-3 moderately resistant cell lines (A427 and H292) exhibit the highest sensitivity to the dual chemical inhibitor of mTOR-PI3K whereas the Nutlin-3 sensitive cell line (H1944) appeared to be relatively insensitive to this inhibitor. These results confirmed our prediction of the master regulator mTOR in the PI3K signaling pathway, which, most probably, is responsible for the elevated resistance of particular NSCLC cell lines to treatment by the p53-reactivating compound Nutlin-3.
Discussion
Resistance to chemotherapy and targeted therapy of cancer cells is one of the biggest problems of cancer treatment. In this work, we studied the molecular mechanisms of resistance of cancer cells to the p53-reactivating compound Nutlin-3 using genome-wide transcriptomics profiling followed by causative computational analysis. In order to analyze Finally, after performing the search for potential master regulators, we checked which of them were actually up-regulated by themselves. So we require that genes, which are expressing proteins that were found by the algorithm as potential master regulators, should have a significantly higher expression in the resistant cells compared to the sensitive cells.
This reflects the presence of positive feedback loops in the system. We hypothesized that the observed increase of resistance might be supported by the presence of positive feedback loops. We can observe such loops in the network when the genes, expressing masterregulator proteins, are working under control of transcription factors, which receive activating signals through the signaling cascade, starting from the proteins, which are expressed by these genes (master regulators). Therefore, the up-regulation of those genes, encoding master regulators in this analysis, indicates the presence of such feedback loops.
We think that such positive feedback loops can contribute to the stabilization of the resistance to Nutlin-3 (and potentially to other anticancer compounds with similar mechanisms of action, such as p53 reactivator molecule RITA, which was studied in our previous work [21] ), since they maintain the constant activation of a certain set of critically important genes through the auto-activation loop.
As a result, we revealed the following master regulator genes: MTOR, DVL3, FOXM1, CAV1. We noticed that many of the suggested master regulators are very important proteins that are known to be involved in regulating such processes as cell cycle and apoptosis.
Finally, we found that Nutlin-3 moderately resistant cell lines (A427 and H292) exhibit the highest sensitivity to the dual chemical inhibitor of mTOR-PI3K, whereas the Nutlin-3 sensitive cell line (H1944) appeared to be relatively insensitive to this inhibitor.
These results confirmed our prediction of the master regulators in the mTOR-PI3K signaling pathway responsible for the elevated resistance of particular NSCLC cell lines to treatment by the p53-reactivating compound Nutlin-3. As we predicted, the Nutlin-3 resistant cell lines 
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